- Home
- FEMY vs GDTC Comparison
FEMY vs GDTC Comparison
Compare FEMY & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- GDTC
- Stock Information
- Founded
- FEMY 2004
- GDTC 2018
- Country
- FEMY United States
- GDTC Singapore
- Employees
- FEMY N/A
- GDTC N/A
- Industry
- FEMY Medical/Dental Instruments
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- GDTC Health Care
- Exchange
- FEMY Nasdaq
- GDTC Nasdaq
- Market Cap
- FEMY N/A
- GDTC 28.0M
- IPO Year
- FEMY 2021
- GDTC 2023
- Fundamental
- Price
- FEMY $1.24
- GDTC $2.46
- Analyst Decision
- FEMY Strong Buy
- GDTC Buy
- Analyst Count
- FEMY 2
- GDTC 1
- Target Price
- FEMY $11.50
- GDTC $5.00
- AVG Volume (30 Days)
- FEMY 312.4K
- GDTC 32.8K
- Earning Date
- FEMY 05-08-2025
- GDTC 01-01-0001
- Dividend Yield
- FEMY N/A
- GDTC N/A
- EPS Growth
- FEMY N/A
- GDTC N/A
- EPS
- FEMY N/A
- GDTC N/A
- Revenue
- FEMY $1,629,108.00
- GDTC $330,254.00
- Revenue This Year
- FEMY $441.89
- GDTC $14.71
- Revenue Next Year
- FEMY $101.29
- GDTC N/A
- P/E Ratio
- FEMY N/A
- GDTC N/A
- Revenue Growth
- FEMY 51.97
- GDTC N/A
- 52 Week Low
- FEMY $0.86
- GDTC $1.20
- 52 Week High
- FEMY $1.80
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- FEMY 47.53
- GDTC 49.89
- Support Level
- FEMY $1.07
- GDTC $2.26
- Resistance Level
- FEMY $1.19
- GDTC $2.53
- Average True Range (ATR)
- FEMY 0.10
- GDTC 0.25
- MACD
- FEMY -0.00
- GDTC 0.01
- Stochastic Oscillator
- FEMY 64.29
- GDTC 55.38
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.